VERAXA Biotech AG (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase, following the completion of its collaboration with OmniAb. The company now plans to engineer the final candidate using its proprietary antibody-engineering, linker, and conjugation technologies, and to conduct in vitro and in vivo preclinical studies. This progression marks a significant step forward for VERAXA's oncology pipeline, which includes ADCs, T-cell engagers, and other engineered antibody formats. For investors, the move signals tangible progress in translating the company's platform technologies into viable therapeutic candidates.
The VXA-222 program employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells while sparing healthy tissue. This approach could address a major challenge in oncology: improving the therapeutic window of ADCs. By targeting two antigens, VXA-222 may reduce off-tumor toxicity and enhance efficacy, a key differentiator in a crowded ADC landscape. The company's broader pipeline, including bispecific T-cell engagers and ADCs, positions it as a rising player in next-generation antibody therapeutics.
VERAXA has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms and related payload, click-chemistry, and conjugation technologies. These filings add to an intellectual-property portfolio that already includes more than 50 granted patents across 26 families in 14 countries. Such robust IP protection is critical for biotech firms seeking to attract partnerships and investment, as it safeguards core innovations and provides a competitive moat. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research.
The advancement of VXA-222 and the expansion of VERAXA's patent estate underscore the company's commitment to building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline into clinical development and beyond. For regular updates about VERAXA Biotech, visit www.VERAXA.com. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers. Through such channels, VERAXA's progress reaches a wide audience of investors and industry stakeholders, amplifying the significance of its development milestones.
For investors, the key takeaway is that VERAXA is not only advancing a promising candidate but also strengthening its foundational IP and platform technologies. This dual focus could enhance the company's value proposition and partnership potential in the competitive biotech sector. As VXA-222 moves toward preclinical studies, the coming months will be critical in demonstrating its potential. With a solid patent portfolio and a pipeline of innovative formats, VERAXA is positioning itself for long-term growth and impact in oncology therapeutics.
